Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Bone Marrow Transplant
    August 2025
  1. DONG Y, Yang T, Zhao M, Song F, et al
    Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
    >> Share

    June 2025
  2. BEKADJA MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, et al
    Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664.
    >> Share

  3. DHOLARIA B, Bhaskar ST, Patel VG, Biltibo E, et al
    Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial.
    Bone Marrow Transplant. 2025;60:769-772.
    >> Share

    May 2025
  4. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
    Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
    >> Share

    April 2025
  5. ABRAMOVICH A, Adam E, Shapira A, Hutt D, et al
    CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615.
    >> Share

  6. MARTINEZ C, Khvedelidze I, Fekom M, Deau Fischer B, et al
    Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA,
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568.
    >> Share

  7. DREGER P, Ahmed S, Bazarbachi A, Dietrich S, et al
    How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
    Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599.
    >> Share

  8. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
    Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
    >> Share

  9. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    >> Share

    March 2025
  10. CANELO-VILASECA M, Sabbah M, Di Blasi R, Cristinelli C, et al
    Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
    Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539.
    >> Share

  11. KHARFAN-DABAJA MA, Mohty R, Easwar N, Johnston P, et al
    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
    Bone Marrow Transplant. 2025 Mar 1. doi: 10.1038/s41409-025-02541.
    >> Share

  12. LOSI G, Mussetti A, Pena M, Lopez-Pereira P, et al
    Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.
    Bone Marrow Transplant. 2025;60:259-269.
    >> Share

    February 2025
  13. KRAMER I, Konig L, Luft T, Hegenbart U, et al
    Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02522.
    >> Share

  14. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    >> Share

  15. CORONA M, Ip A, Brown S, Luna A, et al
    Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 1. doi: 10.1038/s41409-025-02519.
    >> Share

    December 2024
  16. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    >> Share

  17. RAMDIAL J, Lin R, Thall PF, Valdez BC, et al
    High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
    Bone Marrow Transplant. 2024;59:1754-1762.
    >> Share

    November 2024
  18. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    >> Share

  19. RICHARDSON T, Tharmaseelan H, Frenzel L, Godel P, et al
    Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02472.
    >> Share

  20. ZHANG X, Xu K, Gale RP, Pan B, et al
    Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02463.
    >> Share

    October 2024
  21. BRAMANTI S, Mannina D, Chiappella A, Casadei B, et al
    Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study.
    Bone Marrow Transplant. 2024 Oct 9. doi: 10.1038/s41409-024-02427.
    >> Share

  22. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    >> Share

    September 2024
  23. NISHIKUBO M, Shimomura Y, Nakaya Y, Shinohara A, et al
    Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02423.
    >> Share

    August 2024
  24. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    >> Share

  25. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    >> Share

    April 2024
  26. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
    >> Share

    March 2024
  27. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    >> Share

  28. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
    >> Share

    February 2024
  29. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    >> Share

  30. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
    A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
    >> Share

  31. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    >> Share

  32. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    >> Share

    January 2024
  33. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
    Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
    >> Share

  34. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    >> Share

  35. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    >> Share

  36. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    >> Share

  37. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    >> Share

    December 2023
  38. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    >> Share

  39. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    >> Share

  40. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    >> Share

  41. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    >> Share

    November 2023
  42. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    >> Share

  43. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    >> Share

    October 2023
  44. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    >> Share

  45. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    >> Share

    September 2023
  46. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    >> Share

  47. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016